BDR Pharmaceutical, a leading pharma company, announced the launch of the first-of-its kind generic drug, Zisavel capsules, for the treatment of invasive aspergillosis and mucormycosis.
Zisavel belongs to the family of isavuconazole, a class of medications called azole antifungals. Isavuconazole plays an important role in the treatment of invasive aspergillosis.
The product will be available as 100 mg capsules and is the first line of treatment for the aforementioned fungal infections. The price of the generic drug will be Rs. 7,992/-, for 7 capsules which is 1/3rd the cost of present therapy available by Innovators.
BDR Pharmaceutical aims to reduce the cost of therapy for invasive fungal diseases with isavuconazole to be on par with voriconazole and posaconazole (new-generation anti-fungal agents), making it more accessible to patients who are unable to afford it currently.
According to the statistics, the incidence rate of mucormycosis varies globally from 0.005 to 1.7 per million people. In India, the prevalence of mucormycosis is estimated at 140 per million people, 70–80 times higher than in any developed country. With regards to aspergillosis cases in India, the annual incidence of invasive aspergillosis is estimated at 2,50,900 cases, including chronic obstructive pulmonary disease, lung cancer, leukaemia, lymphoma, or transplantation. In the year 2020, invasive aspergillosis cases will have accounted for approximately 2,360 deaths.
The global antifungal drugs market size was valued at USD 15.80 billion in 2022 and is projected to witness at a compound annual growth rate (CAGR) of 3.74% from 2023 to 2030. The growing prevalence of fungal infections such as aspergillosis and candidiasis is one of the key factors propelling the market. The India anti-fungal drugs market is estimated to be valued at US$ 1.56273 billion in 2021 and is expected to exhibit a CAGR of 10.49% over the forecast period (2021-2030).
Talking about the need for and accessibility of the drugs Raheel Shah, director of business development, BDR Group, said, "As medical science progresses and R&D strengthens, we will continue to meet our commitment of providing quality and affordable drugs to needy patients. The burden of fungus diseases varies substantially based on geography, type of infection, severity of the disease, and various other socioeconomic factors. This drug, developed by us, is a revolutionary product, available at 1/3 of the innovator brand price. Isavuconazole will play an important role in controlling the infection and overall life expectancy."
He further added, "As a company, we believe that access to affordable healthcare is a fundamental right for every individual. We are committed to doing everything in our power to make our mucormycosis drug accessible and affordable to all those who need it, and we will continue to work towards a future where no one has to suffer due to a lack of access to healthcare."
With the launch of this new drug, BDR Pharmaceutical addresses a significant gap in the therapy area, particularly for those patients belonging to underprivileged communities.
BDR Group of companies has grown steadily and become a household name in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!